Navigation Links
Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology
Date:11/19/2019

Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital PCR technology, to help advance epigenomics research.

Diagenode’s scATAC-Seq Services leverage the combined capabilities of Bio-Rad’s Droplet Digital PCR (ddPCR) technology and Diagenode’s epigenetics expertise to help researchers gain a greater understanding of the epigenome, the multitude of chemical compounds and proteins that give instructions to the genome. The scATAC-Seq Services utilize Bio Rad’s ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets and offer robust precision and quantification of data.

scATAC-Seq solutions enable the genome-wide study of accessible chromatin that represents regulatory regions at the single-cell level. In contrast to standard bulk ATAC-Seq, scATAC-Seq provides a way for thousands of cells to be assessed in parallel to better parse heterogeneous populations.

“We are excited to offer scientists the combination of Diagenode’s epigenetic service excellence and Bio-Rad’s industry-leading scATAC-Seq technology,” said Joe Bertelsen, Business Unit Manager at Diagenode. “This collaboration demonstrates our continued commitment to enabling advances in epigenomics research.”

“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market,” said Kris Simonyi, Global Marketing Manager at Bio-Rad’s Digital Biology Group. “By working together to combine our expertise, we look forward to accelerating epigenetics and gene regulation research at the single-cell level.”

To learn more about Diagenode’s Single-Cell ATAC-Seq Services, please visit: https://www.diagenode.com/p/single-cell-atac-seq-service
BIO-RAD, DDPCR, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit http://www.bio-rad.com.

About Diagenode, Inc.
Diagenode is a leading provider of complete solutions for epigenetic research and epigenomics services. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high-quality antibodies to streamline DNA methylation, noncoding RNA-seq, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIPmentation and ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Read the full story at https://www.prweb.com/releases/diagenode_to_offer_single_cell_atac_seq_services_featuring_bio_rads_droplet_digital_pcr_technology/prweb16727484.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Diagenode Announces Acquisition of Service Provider NXT-Dx to Complement Epigenetics Assay Services
2. Diagenode Gains Exclusive Rights to New ChIPmentation Technology for Chromatin Immunoprecipitation with High Throughput Sequencing
3. Large animal models of Huntingtons disease offer new and promising research options
4. AegisCare Offers Specialized Home Health Care for Dementia and Alzheimers Patients
5. Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
6. Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research
7. New report offers science-based strategies for management of western free-ranging horses and burros
8. Gene offers an athletes heart without the exercise
9. Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies
10. First-ever therapeutic offers hope for improving blood transfusions
11. MacaInfo.org Offers In-Depth Answers the 20 Most Common Questions People Have about Maca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2020)... (PRWEB) , ... August 19, 2020 , ... ... Salimetrics LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than ... the recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva ...
(Date:8/7/2020)... FRANCISCO (PRWEB) , ... August 06, 2020 , ... ... life sciences industry, is pleased to announce that Eric Chen and Jessica Wong ... President of Product Management & Strategy, respectively. , Eric Chen heads development efforts ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the ... the history of eSource, the reasons it did not take off as quickly as ... source, the industry is moving towards capturing data electronically for clinical trials and then ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
Breaking Biology Technology: